Grace Therapeutics Inc (GRCE)

$4.20 +0.14 (3.45%)
Market Cap 64.99M
Revenue (ttm) 0.00
Net Income (ttm) -9.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 372,700
Avg Vol 195,684
Day's Range N/A - N/A
Shares Out 15.47M
Stochastic %K 58%
Beta 0.71
Analysts Strong Sell
Price Target $11.83

Company Profile

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgi...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 322 1602
Address:
103 Carnegie Center, Suite 300, Princeton, United States
CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 15 at 3:29 PM
$GRCE $6
0 · Reply
JujuInvestor2013
JujuInvestor2013 Mar. 14 at 11:02 AM
$GRCE next week 5$ 🙏🫶🚀
1 · Reply
basssque
basssque Mar. 13 at 4:30 PM
$GRCE Added here at $4.04, nicely discounted with the sector being down
0 · Reply
Blaze321
Blaze321 Mar. 13 at 3:54 PM
$ISPC I am sorry for all the posts today but it really sucks losing ALOT of money. Thankfully I researched this company and got rid of it quickly. Hopefully you kill them on the next one. $GRCE and $CABA are on my radar. I encourage you to do some research. Good Luck All!!!
1 · Reply
Zeit59
Zeit59 Mar. 13 at 3:11 PM
$GRCE Undervalued. ( Fair value at 4.62, PT at 11 ) And here is the catalyst activity: Orphan/rare disease indication (aSAH) = high pricing power (~$500K+ per patient potential). PDUFA in ~6 weeks (April 23) — binary but positive skew if approved. Non-dilutive capital potential (PRV sale precedent in similar names).
0 · Reply
aletz
aletz Mar. 13 at 10:33 AM
$GRCE https://www.biostockinfo.com/biotech-catalyst-ai-scanner-march-wk3/ #6 pick from March Week3 AI scanner. Visit the link for more ideas.
0 · Reply
P0lish
P0lish Mar. 13 at 1:16 AM
$GRCE All 5 thesis pillars intact: 1. ✅ No AdCom (Day 13 clean) 2. ✅ 505(b)(2) path (reformulation — lower regulatory bar) 3. ✅ Cash funded to profitability (no pre-PDUFA dilution) 4. ✅ Institutional accumulation (Renaissance Technologies +53.5% Q4, ADAR1 Capital PIPE below $3.18) 5. ✅ Clinical momentum (AHA/ASA actively drafting IV nimodipine management guidelines)
0 · Reply
BB_88_
BB_88_ Mar. 12 at 8:17 PM
$GRCE more eyes with the cross of 5. Like to see a 3x
0 · Reply
basssque
basssque Mar. 12 at 6:51 PM
$GRCE The next month will be interesting, doesn’t take much to make a big move
0 · Reply
jjangles123
jjangles123 Mar. 12 at 6:29 PM
$GRCE setting my Sell @ 5.00$
0 · Reply
Latest News on GRCE
Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 8:00 AM EST - 18 days ago

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

Feb 12, 2026, 8:00 AM EST - 4 weeks ago

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference

Nov 17, 2025, 8:00 AM EST - 4 months ago

Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference

Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update

Nov 13, 2025, 8:00 AM EST - 4 months ago

Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update

Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting

Nov 11, 2025, 8:30 AM EST - 4 months ago

Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting

Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

Oct 23, 2025, 8:00 AM EDT - 5 months ago

Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

Sep 22, 2025, 8:00 AM EDT - 6 months ago

Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104

Sep 18, 2025, 8:30 AM EDT - 6 months ago

Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104

Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:00 AM EDT - 6 months ago

Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104

Aug 27, 2025, 8:00 AM EDT - 7 months ago

Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104

Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update

Aug 12, 2025, 8:00 AM EDT - 7 months ago

Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104

Jun 25, 2025, 8:00 AM EDT - 9 months ago

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104

Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

Jun 23, 2025, 8:00 AM EDT - 9 months ago

Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

Grace Therapeutics to Participate in the 2025 BIO International Conference

Jun 13, 2025, 8:00 AM EDT - 9 months ago

Grace Therapeutics to Participate in the 2025 BIO International Conference

Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

MTNB

Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 8:00 AM EST - 1 year ago

Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

Feb 13, 2025, 8:00 AM EST - 1 year ago

Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study

Feb 10, 2025, 12:05 PM EST - 1 year ago

Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

Feb 10, 2025, 8:05 AM EST - 1 year ago

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Feb 10, 2025, 8:01 AM EST - 1 year ago

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Jan 7, 2025, 8:00 AM EST - 1 year ago

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Oct 25, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Sep 25, 2024, 7:30 AM EDT - 1 year ago

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 10:35 AM EDT - 1 year ago

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Jun 27, 2024, 4:05 PM EDT - 1 year ago

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

Acasti Pharma to Attend BIO International Convention 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

Acasti Pharma to Attend BIO International Convention 2024

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Feb 12, 2024, 8:00 AM EST - 2 years ago

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Feb 1, 2024, 8:00 AM EST - 2 years ago

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

Dec 13, 2023, 8:00 AM EST - 2 years ago

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Nov 13, 2023, 8:00 AM EST - 2 years ago

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

Oct 4, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

Acasti Announces $7.5 Million Private Placement Equity Financing

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces $7.5 Million Private Placement Equity Financing

Acasti to Participate in the H.C. Wainwright Global Investment Conference

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Acasti to Participate in the H.C. Wainwright Global Investment Conference

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

Jul 10, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

Acasti Pharma Announces 1-for-6 Reverse Stock Split

Jul 7, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma Announces 1-for-6 Reverse Stock Split

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

Jul 5, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

Acasti Pharma Reports Fiscal Year 2023 Operational Results

Jun 23, 2023, 7:00 AM EDT - 2 years ago

Acasti Pharma Reports Fiscal Year 2023 Operational Results

Acasti Announces Appointment of New Scientific Advisory Board Members

Jun 22, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces Appointment of New Scientific Advisory Board Members

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

May 17, 2023, 9:00 AM EDT - 3 years ago

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

May 8, 2023, 7:00 AM EDT - 3 years ago

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

Apr 4, 2023, 8:01 AM EDT - 3 years ago

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

Acasti Announces Appointment of Prashant Kohli as CEO

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Acasti Announces Appointment of Prashant Kohli as CEO

Acasti Pharma Inc. Announces the Resignation of a Director

Mar 30, 2023, 8:30 AM EDT - 3 years ago

Acasti Pharma Inc. Announces the Resignation of a Director

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

Mar 13, 2023, 8:00 AM EDT - 3 years ago

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 15 at 3:29 PM
$GRCE $6
0 · Reply
JujuInvestor2013
JujuInvestor2013 Mar. 14 at 11:02 AM
$GRCE next week 5$ 🙏🫶🚀
1 · Reply
basssque
basssque Mar. 13 at 4:30 PM
$GRCE Added here at $4.04, nicely discounted with the sector being down
0 · Reply
Blaze321
Blaze321 Mar. 13 at 3:54 PM
$ISPC I am sorry for all the posts today but it really sucks losing ALOT of money. Thankfully I researched this company and got rid of it quickly. Hopefully you kill them on the next one. $GRCE and $CABA are on my radar. I encourage you to do some research. Good Luck All!!!
1 · Reply
Zeit59
Zeit59 Mar. 13 at 3:11 PM
$GRCE Undervalued. ( Fair value at 4.62, PT at 11 ) And here is the catalyst activity: Orphan/rare disease indication (aSAH) = high pricing power (~$500K+ per patient potential). PDUFA in ~6 weeks (April 23) — binary but positive skew if approved. Non-dilutive capital potential (PRV sale precedent in similar names).
0 · Reply
aletz
aletz Mar. 13 at 10:33 AM
$GRCE https://www.biostockinfo.com/biotech-catalyst-ai-scanner-march-wk3/ #6 pick from March Week3 AI scanner. Visit the link for more ideas.
0 · Reply
P0lish
P0lish Mar. 13 at 1:16 AM
$GRCE All 5 thesis pillars intact: 1. ✅ No AdCom (Day 13 clean) 2. ✅ 505(b)(2) path (reformulation — lower regulatory bar) 3. ✅ Cash funded to profitability (no pre-PDUFA dilution) 4. ✅ Institutional accumulation (Renaissance Technologies +53.5% Q4, ADAR1 Capital PIPE below $3.18) 5. ✅ Clinical momentum (AHA/ASA actively drafting IV nimodipine management guidelines)
0 · Reply
BB_88_
BB_88_ Mar. 12 at 8:17 PM
$GRCE more eyes with the cross of 5. Like to see a 3x
0 · Reply
basssque
basssque Mar. 12 at 6:51 PM
$GRCE The next month will be interesting, doesn’t take much to make a big move
0 · Reply
jjangles123
jjangles123 Mar. 12 at 6:29 PM
$GRCE setting my Sell @ 5.00$
0 · Reply
ReelHeel98
ReelHeel98 Mar. 12 at 6:27 PM
$GRCE someone is trying hard to keep this from running!
1 · Reply
ViVega1
ViVega1 Mar. 12 at 4:13 PM
$GRCE Azurity lurking? Don't believe. But why not?
0 · Reply
Stockseeking
Stockseeking Mar. 12 at 4:01 PM
$GRCE may be earlier approval?
0 · Reply
ViVega1
ViVega1 Mar. 12 at 3:54 PM
$GRCE volume is crazy today, actually 1,155,000 shares traded, 10 times more than average. It means nearly 5 million or 10 % of mc. What is going on? Just pre FDA speculation?
2 · Reply
basssque
basssque Mar. 12 at 3:49 PM
$GRCE $GRCE I’m in, looks like the run up to the April 23rd PDUFA date is in full swing now
0 · Reply
BOUDIN420
BOUDIN420 Mar. 12 at 3:46 PM
$GRCE 🎯👇👇
0 · Reply
Stockseeking
Stockseeking Mar. 12 at 3:41 PM
$GRCE still a lot of room to go up, after approval, a minimal of 2x
0 · Reply
Run_Taurus
Run_Taurus Mar. 12 at 3:33 PM
$GRCE
0 · Reply
Stockseeking
Stockseeking Mar. 12 at 3:31 PM
$GRCE good volume, may see 5 today instead of tomorrow or early next week
0 · Reply
Autolus_Freakk
Autolus_Freakk Mar. 12 at 3:18 PM
$GRCE Only 4% short float on this ticker... buyers in control
0 · Reply
Stockseeking
Stockseeking Mar. 12 at 3:16 PM
$GRCE don't sell, the extremely low market cap can push this to really high
0 · Reply
Bellz22
Bellz22 Mar. 12 at 3:12 PM
$GRCE 🚀🚀🚀
0 · Reply